Literature DB >> 11035372

Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients.

J F Tomás1, I Pinilla, M L García-Buey, A García, A Figuera, R Moreno, J M Fernández-Rañada.   

Abstract

This retrospective study has aimed at determining the prevalence, aetiology and clinical evolution of chronic liver disease (CLD) after allogeneic bone marrow transplantation (BMT). A total of 106 patients who had been transplanted in a single institution and who had survived for at least 2 years after BMT were studied. The prevalence of CLD was 57.5% (61/106). In 47.3% of cases more than one aetiopathogenic agent coexisted. The causes of CLD were iron overload (52.4%), chronic hepatitis C (47.5%), chronic graft-versus-host disease (C-GVHD) (37.7%), hepatitis B (6.5%), non-alcoholic steatohepatitis (NASH) (4.9%), autoimmune hepatitis (AIH) (4.9%) and unknown two (3.3%). Twenty-three patients with iron overload underwent venesections which were well tolerated. An improvement in liver function tests (LFTs) was observed in 21 (91%) patients. All six patients with siderosis as the only cause of CLD normalized LFT as well as three patients with HCV infection. Clinical evolution was satisfactory for patients with GVHD, AIH, NASH and hepatitis B. At the last visit 23 patients continued with abnormal LFTs, and 19 of them were infected by the HCV. A sustained biochemical and virologic response was achieved in only one case out of six patients with CHC who received interferon. We have found that CLD is a common complication in long-term BMT survivors. The aetiology is often multifactorial, iron overload, CHC and C-GVHD being the main causes. The CLD followed a rather 'benign' and slow course in our patients as none of them developed symptoms or signs of liver failure and we did not observe an increase in morbidity or mortality in these patients, but a longer follow-up is necessary in HCV infected patients based on the natural history of this infection in other populations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11035372     DOI: 10.1038/sj.bmt.1702532

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  15 in total

Review 1.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 2.  Hepatitis C virus and allogeneic stem cell transplantation still matters!

Authors:  Gérard Socié; Régis Peffault de Latour; George B McDonald
Journal:  Haematologica       Date:  2009-02       Impact factor: 9.941

3.  The treatment of chronic graft-versus-host disease: consensus recommendations of experts from Germany, Austria, and Switzerland.

Authors:  Daniel Wolff; Hartmut Bertz; Hildegard Greinix; Anita Lawitschka; Jörg Halter; Ernst Holler
Journal:  Dtsch Arztebl Int       Date:  2011-10-28       Impact factor: 5.594

4.  National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction.

Authors:  Michael L Nieder; George B McDonald; Aiko Kida; Sangeeta Hingorani; Saro H Armenian; Kenneth R Cooke; Michael A Pulsipher; K Scott Baker
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-01       Impact factor: 5.742

5.  [Complications after allogeneic bone marrow and stem cell transplantation].

Authors:  E Wollmer; A Neubauer
Journal:  Internist (Berl)       Date:  2014-05       Impact factor: 0.743

6.  Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation.

Authors:  Ann-Kathrin Eisfeld; Rainer Krahl; Nadja Jaekel; Dietger Niederwieser; Haifa Kathrin Al-Ali
Journal:  Am J Blood Res       Date:  2012-11-25

7.  Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

Authors:  Carlos A Ramos; Rima M Saliba; Leandro de Pádua; Ola Khorshid; Elizabeth J Shpall; Sergio Giralt; Poliana A Patah; Chitra M Hosing; Uday R Popat; Gabriela Rondon; Issa F Khouri; Yago L Nieto; Richard E Champlin; Marcos de Lima
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

8.  Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.

Authors:  Carlos Vallejo; Montserrat Batlle; Lourdes Vázquez; Carlos Solano; Antonia Sampol; Rafael Duarte; Dolores Hernández; Javier López; Montserrat Rovira; Santiago Jiménez; David Valcárcel; Vicente Belloch; Mónica Jiménez; Isidro Jarque
Journal:  Haematologica       Date:  2014-07-04       Impact factor: 9.941

9.  Chronic graft-versus-host disease of the liver presenting as an acute hepatitis following nonmyeloablative hematopoietic stem cell transplantation.

Authors:  Hoyoung Maeng; Jae-Hyun Lee; June Won Cheong; Seung Tae Lee; Jee Sook Hahn; Yun Woong Ko; Yoo Hong Min
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

10.  Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation.

Authors:  N Jaekel; K Lieder; S Albrecht; O Leismann; K Hubert; G Bug; N Kröger; U Platzbecker; M Stadler; K de Haas; S Altamura; M U Muckenthaler; D Niederwieser; H K Al-Ali
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.